Sikkenk Daan J, Sterkenburg Andrea J, Burghgraef Thijs A, Akol Halil, Schwartz Matthijs P, Arensman René, Verheijen Paul M, Nagengast Wouter B, Consten Esther C J
Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Department of Surgery, Meander Medical Center, Maatweg 3, 3813 TZ, Amersfoort, The Netherlands.
Surg Endosc. 2023 Nov;37(11):8394-8403. doi: 10.1007/s00464-023-10394-2. Epub 2023 Sep 18.
Patients with cT1-2 colon cancer (CC) have a 10-20% risk of lymph node metastases. Sentinel lymph node identification (SLNi) could improve staging and reduce morbidity in future organ-preserving CC surgery. This pilot study aimed to assess safety and feasibility of robot-assisted fluorescence-guided SLNi using submucosally injected indocyanine green (ICG) in patients with cT1-2N0M0 CC.
Ten consecutive patients with cT1-2N0M0 CC were included in this prospective feasibility study. Intraoperative submucosal, peritumoral injection of ICG was performed during a colonoscopy. Subsequently, the near-infrared fluorescence 'Firefly' mode of the da Vinci Xi robotic surgical system was used for SLNi. SLNs were marked with a suture, after which a segmental colectomy was performed. The SLN was postoperatively ultrastaged using serial slicing and immunohistochemistry, in addition to the standard pathological examination of the specimen. Colonoscopy time, detection time (time from ICG injection to first SLNi), and total SLNi time were measured (time from the start of colonoscopy to start of segmental resection). Intraoperative, postoperative, and pathological outcomes were registered.
In all patients, at least one SLN was identified (mean 2.3 SLNs, SLN diameter range 1-13 mm). No tracer-related adverse events were noted. Median colonoscopy time was 12 min, detection time was 6 min, and total SLNi time was 30.5 min. Two patients had lymph node metastases present in the SLN, and there were no patients with false negative SLNs. No patient was upstaged due to ultrastaging of the SLN after an initial negative standard pathological examination. Half of the patients unexpectedly had pT3 tumours.
Robot-assisted fluorescence-guided SLNi using submucosally injected ICG in ten patients with cT1-2N0M0 CC was safe and feasible. SLNi was performed in an acceptable timespan and SLNs down to 1 mm were detected. All lymph node metastases would have been detected if SLN biopsy had been performed.
cT1-2期结肠癌(CC)患者有10%-20%的淋巴结转移风险。前哨淋巴结识别(SLNi)可改善分期,并降低未来保器官CC手术的发病率。这项前瞻性研究旨在评估在cT1-2N0M0期CC患者中使用黏膜下注射吲哚菁绿(ICG)进行机器人辅助荧光引导SLNi的安全性和可行性。
本前瞻性可行性研究纳入了10例连续的cT1-2N0M0期CC患者。在结肠镜检查期间进行术中黏膜下、肿瘤周围注射ICG。随后,使用达芬奇Xi机器人手术系统的近红外荧光“萤火虫”模式进行SLNi。前哨淋巴结用缝线标记,之后进行节段性结肠切除术。除了对标本进行标准病理检查外,术后还通过连续切片和免疫组织化学对前哨淋巴结进行超分期。测量结肠镜检查时间、检测时间(从ICG注射到首次识别前哨淋巴结的时间)和总SLNi时间(从结肠镜检查开始到节段性切除开始的时间)。记录术中、术后和病理结果。
所有患者均至少识别出1个前哨淋巴结(平均2.3个前哨淋巴结,前哨淋巴结直径范围为1-13毫米)。未观察到与示踪剂相关的不良事件。结肠镜检查中位时间为12分钟,检测时间为6分钟,总SLNi时间为30.5分钟。2例患者的前哨淋巴结存在淋巴结转移,无假阴性前哨淋巴结患者。在最初标准病理检查为阴性后,没有患者因前哨淋巴结超分期而被上调分期。半数患者意外发现为pT3期肿瘤。
在10例cT1-2N0M0期CC患者中,使用黏膜下注射ICG进行机器人辅助荧光引导SLNi是安全可行的。SLNi在可接受的时间范围内完成,检测到了小至1毫米的前哨淋巴结。如果进行前哨淋巴结活检,所有淋巴结转移都能被检测到。